The Australia medical cannabis market size was estimated at USD 595.12 million in 2025 and is projected to reach USD 1.63 billion by 2033, growing at a CAGR of 12.85% from 2026 to 2033. This growth is driven by a rising interest in alternative therapies for managing chronic pain, nausea, and various other health issues, the introduction of new products and formulations.
This growth in demand for non traditional therapeutic options reflects a shift in consumer preferences and a growing acknowledgment of the potential health benefits of these alternatives. The market is witnessing a significant increase in new and diverse product offerings, ranging from edibles and topicals.
In addition, number of people adopting cannabis for medical purposes has recently increased in Australia. According to findings from the 2022-23 National Drug Strategy Household Survey, conducted by the Australian Institute of Health and Welfare (AIHW), the use of cannabis for medical reasons has become increasingly common across Australia. The survey indicates that roughly three in every 100 Australians aged 14 years and older reported using cannabis for therapeutic purposes within the previous year, translating to an estimated population of about 700,000 individuals. This data reflects a trend in medical cannabis adoption, highlighting its growing role in symptom management and therapeutic care within the Australian healthcare landscape.
Moreover, the growth in patient numbers is matched by a rise in formal prescriptions, managed through access frameworks set by the Therapeutic Goods Administration (TGA). For instance, data from the TGA published in April 2024, show that since legal access pathways were established in 2016, approvals for medicinal cannabis products have grown substantially. In the end of 2023, there were over 963,000 approvals under the Authorized Prescriber (AP) pathway and around 458,000 approvals under the Special Access Scheme Category B (SAS-B) with chronic pain and anxiety among the top indications for use.
This growth in demand for non traditional therapeutic options reflects a shift in consumer preferences and a growing acknowledgment of the potential health benefits of these alternatives. The market is witnessing a significant increase in new and diverse product offerings, ranging from edibles and topicals.
In addition, number of people adopting cannabis for medical purposes has recently increased in Australia. According to findings from the 2022-23 National Drug Strategy Household Survey, conducted by the Australian Institute of Health and Welfare (AIHW), the use of cannabis for medical reasons has become increasingly common across Australia. The survey indicates that roughly three in every 100 Australians aged 14 years and older reported using cannabis for therapeutic purposes within the previous year, translating to an estimated population of about 700,000 individuals. This data reflects a trend in medical cannabis adoption, highlighting its growing role in symptom management and therapeutic care within the Australian healthcare landscape.
Moreover, the growth in patient numbers is matched by a rise in formal prescriptions, managed through access frameworks set by the Therapeutic Goods Administration (TGA). For instance, data from the TGA published in April 2024, show that since legal access pathways were established in 2016, approvals for medicinal cannabis products have grown substantially. In the end of 2023, there were over 963,000 approvals under the Authorized Prescriber (AP) pathway and around 458,000 approvals under the Special Access Scheme Category B (SAS-B) with chronic pain and anxiety among the top indications for use.
Australia Medical Cannabis Market Report Segmentation
This report forecasts revenue growth at country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2021 to 2033. For the purpose of this study, the analyst has segmented the Australia medical cannabis market report on the basis of sources, derivatives, and application:Sources Outlook (Revenue, USD Million, 2021-2033)
- Hemp
- Marijuana
Derivative Outlook (Revenue, USD Million, 2021-2033)
- CBD
- THC
- Others
Application Outlook (Revenue, USD Million, 2021-2033)
- Cancer
- Chronic Pain
- Anxiety and Depression
- Arthritis
- Diabetes
- Glaucoma
- Migraines
- Epilepsy
- Multiple Sclerosis
- AIDS
- Amyotrophic Lateral Sclerosis
- Alzheimer’s Disease
- Post Traumatic Stress Disorder (PTSD)
- Parkinson's Disease
- Tourette’s Syndrome
- Others
Why You Should Buy This Report
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Australia Medical Cannabis Market Variables, Trends & Scope
Chapter 4. Australia Medical Cannabis Market: Sources Estimates & Trend Analysis
Chapter 5. Australia Medical Cannabis Market: Derivatives Estimates & Trend Analysis
Chapter 6. Australia Medical Cannabis Market: Application Estimates & Trend Analysis
Chapter 7. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The leading players profiled in this Australia Medical Cannabis market report include:- Cann Group
- Zelira Therapeutics
- AusCann Group Holdings Ltd
- Bod Science
- Althea Group
- Ecofibre
- Botanix SB Inc.
- EPSILON
- Little Green Pharma
- Incannex Healthcare
- Vitura Health Limited
- Bioxyne
- Green Farmers
- ECS Botanics
- Tasmanian Botanics
- Cannatrek
- Hale farms
- Australian Natural Therapeutics Group
- MedTEC Pharma
- Aruma Labs
- Montu Group
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 100 |
| Published | February 2026 |
| Forecast Period | 2025 - 2033 |
| Estimated Market Value ( USD | $ 595.12 Million |
| Forecasted Market Value ( USD | $ 1630 Million |
| Compound Annual Growth Rate | 12.8% |
| Regions Covered | Australia |
| No. of Companies Mentioned | 22 |
